OBJECTIVES: The increasing number of longer living patients with follicular lymphoma (FL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population. METHODS: The population-based Eindhoven Cancer Registry was used to select patients diagnosed with FL during 2004-2010. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-yr interval. This questionnaire was also completed by an age- and sex-matched normative population (N = 580). Detailed data on treatment were extracted from the cancer registry and Population-based HAematological Registry for Observational Studies (PHAROS). RESULTS: Of the 181 patients who were invited, 148 responded (82%, T1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy (P = 0.02). No differences were observed on the other HRQoL scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with immunochemotherapy compared with a normative population (P < 0.01). A quarter to 50% of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/HRQoL. CONCLUSION: Alertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQoL.
OBJECTIVES: The increasing number of longer living patients with follicular lymphoma (FL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population. METHODS: The population-based Eindhoven Cancer Registry was used to select patients diagnosed with FL during 2004-2010. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-yr interval. This questionnaire was also completed by an age- and sex-matched normative population (N = 580). Detailed data on treatment were extracted from the cancer registry and Population-based HAematological Registry for Observational Studies (PHAROS). RESULTS: Of the 181 patients who were invited, 148 responded (82%, T1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy (P = 0.02). No differences were observed on the other HRQoL scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with immunochemotherapy compared with a normative population (P < 0.01). A quarter to 50% of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/HRQoL. CONCLUSION: Alertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQoL.
Authors: Joanna M Davies; Thomas R Osborne; Polly M Edmonds; Steve A Schey; Steve Devereux; Irene J Higginson; Christina Ramsenthaler Journal: Eur J Haematol Date: 2017-03-09 Impact factor: 2.997
Authors: Lindy P J Arts; Lonneke V van de Poll-Franse; Sanne W van den Berg; Judith B Prins; Olga Husson; Floortje Mols; Angelique V M Brands-Nijenhuis; Lidwine Tick; Simone Oerlemans Journal: Trials Date: 2017-04-28 Impact factor: 2.279
Authors: Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace Journal: Qual Life Res Date: 2017-11-10 Impact factor: 4.147
Authors: Janneke A J Rood; Birgit I Lissenberg-Witte; Corien Eeltink; Frank Stam; Florence J van Zuuren; Sonja Zweegman; Irma M Verdonck-de Leeuw Journal: PLoS One Date: 2018-08-09 Impact factor: 3.240
Authors: Klaus Herfarth; Peter Borchmann; Sven Schnaidt; Karin Hohloch; Volker Budach; Marianne Engelhard; Andreas Viardot; Rita Engenhart-Cabillic; Ulrich Keller; Gabriele Reinartz; Hans-Theodor Eich; Mathias Witzens-Harig; Clemens F Hess; Bernd Dörken; Jan Dürig; Thomas Wiegel; Wolfgang Hiddemann; Eva Hoster; Christiane Pott; Martin Dreyling Journal: Hemasphere Date: 2018-11-30